Compare BYD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYD | COGT |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 1996 | 2018 |
| Metric | BYD | COGT |
|---|---|---|
| Price | $82.19 | $34.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $90.82 | $36.21 |
| AVG Volume (30 Days) | 854.9K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 264.46 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $2,626,730,000.00 | $7,871,000.00 |
| Revenue This Year | $1.71 | N/A |
| Revenue Next Year | $2.74 | $1,733.58 |
| P/E Ratio | $58.93 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $72.71 | $5.04 |
| 52 Week High | $89.96 | $43.73 |
| Indicator | BYD | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 47.39 |
| Support Level | $80.76 | $33.26 |
| Resistance Level | $84.62 | $37.69 |
| Average True Range (ATR) | 1.85 | 1.28 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 53.72 | 64.55 |
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.